Details

Autor(en) / Beteiligte

• Cubo, Esther
• Doumbe, Jacques
• Martinez-Martin, Pablo
• Rodriguez-Blazquez, Carmen
• Kuate, Callixte
• Mariscal, Natividad
• Lopez, Irene
• Noubissi, Gustave
• Mapoure, Yacouba Njankouo
• Jon, Jean Louis
• Mbahe, Salomon
• Tchaleu, Benjamin
• Catalan, Maria-Jose

Titel

Comparison of the clinical profile of Parkinson's disease between Spanish and Cameroonian Cohorts

Ist Teil von

• Journal of the neurological sciences, 2014-01, Vol.336 (1), p.122-126

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Background There are limited data in terms of the clinical profile of Parkinson's disease in sub-Saharan African patients. Objective To compare the clinical profile and access to standard antiparkinsonian therapies of a Cameroonian cohort of patients with an age, sex, and disease duration-matched Spanish cohort (Longitudinal Study of Parkinson's disease, ELEP). Methods Observational, cross-sectional design. Demographic data were collected and the following ELEP assessments were applied: Scales for Outcomes in Parkinson's disease (SCOPA) Motor, Autonomic, Cognition, Sleep and Psychosocial; Hoehn and Yahr staging; modified Parkinson Psychosis Rating Scale; Cumulative Illness Rating Scale-Geriatrics; Hospital Anxiety and Depression Scale; pain and fatigue visual analog scales; Zarit, and EuroQoL. Results 74 patients with idiopathic Parkinson's disease were included (37 from each country) with a mean age of 64.4 ± 10.5 years old, 70.3% males, and mean disease duration of 5.6 ± 5.9 years. Compared to the Spanish cohort, Cameroonians were intermittently treated, less frequently received dopaminergic agonists (p < 0.001), had a trend for taking lower doses of levodopa (p = 0.06), and were more frequently on anticholinergics (p < 0.0005). Cameroonians were more severely impaired in terms of motor (Hoehn Yahr stage, p = 0.03; SCOPA-Motor, p < 0.001), cognitive status (p < 0.001), anxiety and depression (p < 0.001), psychosis (p = 0.008), somnolence, fatigue and pain (p < 0.001, respectively), caregiver burden (p < 0.0001), and quality of life (p = 0.002). Instead, autonomic, comorbidity, and nocturnal sleep problems were similarly found. Conclusions Limited and intermittent access to dopaminergic drugs has a negative impact on motor symptoms, nonmotor symptoms and quality of life in patients with Parkinson's disease and their caregivers.